Search clinical trials for: Iptacopan (part 2)

Total 18115 results

Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Lupus Nephritis

France, Spain, Israel, Turkey, United States, Germany, India, Hungary, Malaysia, Portugal, Brazil, China, Puerto Rico, Hong Kong, Mexico, Singapore
Janssen Cilag N.V./S.A.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019) (APECS)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment | Prodromal Alzheimer's Disease
Chong Kun Dang Pharmaceutical

Completed

Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1

Type2 Diabetes Mellitus

Korea, Republic of
Novartis Pharmaceuticals

Completed

A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients

Primary Biliary Cholangitis

United States, Germany, Russian Federation, Canada, United Kingdom, Poland
Janssen Research & Development, LLC

Completed

A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis

Healthy | Asthma | Atopic Dermatitis

Germany, Belgium
Pfizer

Completed

A Study in Normal Healthy People, Testing Different Versions of a Pill That Will be Used to Treat Rheumatoid Arthritis.

Rheumatoid Arthritis | Healthy Volunteers

United States
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects (CHF6333 FIH)

Cystic Fibrosis | Non-Cystic Fibrosis Bronchiectasis

Belgium
Bausch & Lomb Incorporated

Completed

Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)

Anaphylaxis

Germany
Sun Pharma Advanced Research Company Limited

Terminated

A Study in Patients With Advanced Breast Cancer

Advanced Breast Cancer | HER2-negative Breast Cancer | Hormone Receptor-positive Breast Cancer

United States, India
Bilthoven Biologicals
Serum Institute of India Pvt. Ltd.

Completed

A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals

Immune Response to Oral Polio Vaccine

Bangladesh
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

CD20-positive B-cell Non-Hodgkin Lymphoma

United States, France
AstraZeneca
Acerta Pharma, LLC

Completed

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

Bioavailability | B-cell Lymphoid Cancer

United States
Chiesi Farmaceutici S.p.A.

Terminated

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD (CHF6297 FIH)

Chronic Obstructive Pulmonary Disease

United Kingdom
Akesobio Australia Pty Ltd

Completed

A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic Dermatitis

Atopic Dermatitis

New Zealand, Australia
Huahui Health

Completed

A Study to Evaluate the Safety and Pharmacokinetics of HH-120 Nasal Spray in Healthy Volunteers

COVID-19

China
Ichnos Sciences SA
Glenmark Pharmaceuticals S.A.

Completed

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

United States, Canada, Czechia, Germany, Poland
UCB Pharma
Parexel

Completed

Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject

Psoriasis

United Kingdom
Tetherex Pharmaceuticals Corporation

Completed

Study to Assess the Safety and Efficacy of SelK2 on Airway Responses Following Allergen Challenge in Subjects With Asthma (Part 1) and in Subjects With Chronic Obstructive Pulmonary Disease (Part 2)

Chronic Obstructive Pulmonary Disease | Asthma

United Kingdom
Institute of Cancer Research, United Kingdom
Trans Tasman Radiation Oncology Group

Active, not recruiting

Study of Tumour Focused Radiotherapy for Bladder Cancer (RAIDER)

Bladder Cancer

United Kingdom, New Zealand, Australia
Bukwang Pharmaceutical

Active, not recruiting

Study in Parkinson's Disease Patients With Dyskinesia With Combinations of JM-010 and Its Individual Components (SHINE)

Parkinson Disease | Dyskinesias

United States
GlaxoSmithKline

Withdrawn

A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Cancer

Australia
Novartis Pharmaceuticals

Recruiting

Long-term Efficacy, Safety and Tolerability of LNP023 in C3G

C3 Glomerulopathy

Spain, France, Germany, Switzerland, United States, Japan, Turkey, China, United Kingdom, Italy, Argentina, Brazil, Greece, Israel, Netherlands
Novartis Pharmaceuticals

Completed

Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.

Hepatic Impairment

United States
Wake Forest University Health Sciences

Completed

Social Determinants of Health in Glioblastoma Population

Glioma | Astrocytoma | Ependymoma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Oligodendroglioma

United States
Daewoong Pharmaceutical Co. LTD.

Terminated

Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo

Mild to Moderate COVID-19

Korea, Republic of
Axalbion SA

Completed

AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects

Healthy

United Kingdom
M.D. Anderson Cancer Center

Terminated

Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems

Skin Cancer

United States
Bilix Co.,Ltd.

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of BX-001N in Healthy Participants

Ischemia-reperfusion Injury

Australia
Actimed Therapeutics Ltd
Quotient Sciences

Completed

Study of Comparative Bioavailability and Pharmacokinetics of ACM-001.1) and Pindolol in Healthy Volunteers (HV)

Cachexia

United Kingdom
Kanyos Bio, Inc., a wholly-owned subsidiary of...
Pfizer

Recruiting

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

Celiac Disease

United States, Australia, New Zealand
Novartis Pharmaceuticals

Recruiting

A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

Age-Related Macular Degeneration

China, United States, United Kingdom, Puerto Rico
Elpiscience Biopharma, Ltd.

Active, not recruiting

A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumor

United States
Novartis Pharmaceuticals

Active, not recruiting

Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders

Immune Thrombocytopenia (ITP) | Cold Agglutinin Disease (CAD)

United States, Spain, Germany, Korea, Republic of, United Kingdom, Italy
Enanta Pharmaceuticals, Inc

Terminated

A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.

Chronic Hepatitis B Virus Infection

New Zealand
National Institute for Tuberculosis and Lung Diseases...

Recruiting

PEP and OPEP Devices in Cystic Fibrosis

Cystic Fibrosis

Poland
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)

Sickle Cell Disease

United States
iN Therapeutics Co., Ltd.

Recruiting

A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.

Pain | Osteoarthritis | Chronic Pain | Neuropathic Pain | Post Herpetic Neuralgia

Australia
National Taiwan University Hospital
National Taiwan University Hospital, Yun-Lin Branch

Recruiting

Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

Taiwan
Korea Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.

Completed

OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects. (OPS-2071Ph1)

Healthy

Korea, Republic of
NYU Langone Health

Completed

Visible Light Study

Skin Disease | Pigment Disorders

United States
ImmunityBio, Inc.

Recruiting

QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

Metastatic Solid Tumor

United States
AstraZeneca

Completed

Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Volunteers

Healthy

United Kingdom
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

CML, Chronic Phase | CML, Accelerated Phase

China
Kadmon Corporation, LLC
Quotient Sciences

Completed

A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative Bioavailability

Healthy Volunteers

United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma

Tumor or Lymphoma

United States, France, Spain
Sun Pharmaceutical Industries Limited

Completed

Efficacy and Safety of Tildrakizumab in the Treatment of Scalp Psoriasis

Scalp Psoriasis

United States, Australia
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy (APPOINT-PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

China, Germany, Singapore, Korea, Republic of, Italy, United Kingdom, Malaysia, France
Verrica Pharmaceuticals Inc.
Instat Clinical Research; HeartcoR Solutions; Myonex; Vial Health Technology, Inc

Recruiting

Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma

Carcinoma | Skin Cancer | Basal Cell Carcinoma | Cancer of the Skin, Basal Cell | Cancer of the Skin

United States
M.D. Anderson Cancer Center

Withdrawn

STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis

Acute Myeloid Leukemia (AML) | Refractory T Acute Lymphoblastic Leukemia

United States

Search clinical trials for: Iptacopan (part 2)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations